产品名称 | NebuSelect™ Recombinant Human LRG1, His-tag |
---|---|
目录号 | NBL-242332 |
别名 | LRG1; Leucine-rich alpha-2-glycoprotein; LRG;LRG1 |
外观 | see COA |
分子量 | |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | P02750 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242332-100ug | 100ug | Inquire | Inquire | |
NBL-242332-1mg | 1mg | Inquire | Inquire | |
NBL-242332-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human LRG1, His-tag
Catalog#:
NBL-242332
Description:
NebuSelect™ Recombinant Human LRG1, His-tag(Cat#NBL-242332) is expressed in HEK293 with His tag at the C-Terminus.It contains Val36-Gln347.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 35.4 kDa. Due to glycosylation, the protein migrates to 48-52 kDa based on Bis-Tris PAGE result.
Target Name:
LRG1; Leucine-rich alpha-2-glycoprotein; LRG;LRG1
Target Information:
Diabetic nephropathy (DN) is an important public health concern of increasing proportions and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the most common long-term microvascular complications of diabetes mellitus that is characterized by proteinuria and glomerular structural changes. LRG1 is a novel pro-angiogenic factors involved in the abnormal angiogenesis and renal fibrosis in DN.
Amino Acid Sequence:
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.